-
AnthonyAbefs
SMM-продвижение в социальных сетях: услуги
Статья охватывает все этапы SMM-продвижения: от брифа и стратегии до запуска кампаний и оптимизации. Понравилось, что автор уделяет внимание не только креативу, но и аналитике, а также даёт советы по тестированию гипотез. Рекомендую к прочтению: <a href="https://iwatt24.ru/uslugi-smm/">https:/ ... gi-smm/</a>
-
JamesFruth
301 Moved Permanently
Коллеги, кто хочет разобраться в SEO, рекомендую эту статью. Там объясняют, почему продвижение — это долгосрочная инвестиция, а не разовая акция. Есть примеры и чёткая структура. Почитайте: <a href="https://runeterra-wiki.ru/seo-prodvizhe ... anstve/</a>
-
LincolnVodia
Zoya Demidenko https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-of-Mutant-p53-and-Cytotoxicity-of
Zoya Demidenko: Scientist in Cancer Biology
Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, establishing a strong foundation in clinical study.
Her scientific contributions spans multiple pivotal domains, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, cell senescence, and malignancy science. To date, she has authored over 46 scientific publications, which have garnered over 4,100 citations — a reflection to the influence of her findings.
One of her most notable achievements concerns explaining the pathways of biological cell aging. Her work revealed that when the cell cycle is halted while cellular expansion persists, the cells experience senescence. Importantly, Zoya Demidenko established that this process can be controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko has furthermore brought considerably to tumor management investigation, notably in the field of cyclotherapy — a method aimed at protecting healthy tissue from cytotoxic treatment while leaving cancer cells susceptible. This approach offers considerable hope for diminishing the side effects of cancer treatment.
Throughout her professional journey, Demidenko has partnered with top researchers internationally, such as Dr. Mikhail Blagosklonny. Her work can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a widely cited figure in contemporary oncological science, whose discoveries continue to influence our knowledge of the way cells grow old, resist treatment, and the ways in which cancer may be more effectively treated.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/
Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, establishing a strong foundation in clinical study.
Her scientific contributions spans multiple pivotal domains, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, cell senescence, and malignancy science. To date, she has authored over 46 scientific publications, which have garnered over 4,100 citations — a reflection to the influence of her findings.
One of her most notable achievements concerns explaining the pathways of biological cell aging. Her work revealed that when the cell cycle is halted while cellular expansion persists, the cells experience senescence. Importantly, Zoya Demidenko established that this process can be controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko has furthermore brought considerably to tumor management investigation, notably in the field of cyclotherapy — a method aimed at protecting healthy tissue from cytotoxic treatment while leaving cancer cells susceptible. This approach offers considerable hope for diminishing the side effects of cancer treatment.
Throughout her professional journey, Demidenko has partnered with top researchers internationally, such as Dr. Mikhail Blagosklonny. Her work can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a widely cited figure in contemporary oncological science, whose discoveries continue to influence our knowledge of the way cells grow old, resist treatment, and the ways in which cancer may be more effectively treated.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/